Pregnancy Termination and Postnatal Major Congenital Heart Defect Prevalence After Introduction of Prenatal Cardiac

Viktor Tomek1, Hana Jicínská2, Jan Pavlícek3

  • 1Children's Heart Centre, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, the Czech Republic.

JAMA Network Open
|September 15, 2023
PubMed

Insights

Prenatal screening significantly improved congenital heart defect (CHD) detection rates, leading to a decrease in postnatal prevalence. However, early first-trimester screening increased termination rates for CHDs, without altering the overall trend.

Area of Science:

  • Cardiology
  • Prenatal Diagnostics
  • Public Health

Background:

  • Prenatal cardiac screening impacts congenital heart defect (CHD) prevalence, pregnancy terminations, and outcomes for affected children.
  • Understanding trends in CHD detection and management is crucial for improving prenatal care.

Purpose of the Study:

  • To analyze the incidence, detection rates, and termination trends of major CHDs over 31 years.
  • To assess the association between prenatal cardiac screening and postnatal outcomes.

Main Methods:

  • A 31-year cross-sectional study (1991-2021) in the Czech Republic.
  • Involved analysis of 3827 fetuses with antenatally diagnosed major CHDs and 5454 live-born children with major CHDs using national registries.

Main Results:

  • Prenatal detection of major CHDs increased from 6.2% to 82.8%.
  • Postnatal prevalence of major CHDs decreased from 0.21% to 0.14%.
  • First-trimester screening (introduced 2007) showed higher termination rates (73.3%) compared to second-trimester screening (42.6%).

Conclusions:

  • The total incidence of major CHDs remained stable, but postnatal prevalence declined due to increased prenatal detection and terminations.
  • While first-trimester screening improved early detection, it also raised termination rates, though the overall trend for CHD termination decreased.
  • Prenatal screening has significantly reshaped the landscape of CHD management and outcomes.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
16
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
21
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
56
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
20
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
15